SCIENMAG: Medicine & Health

JUNE 26, 2023

CDT, Tuesday, June 27, 2023)—By monitoring early-response biomarkers in men undergoing 177Lu-PSMA prostate cancer treatment, physicians can personalize dosing intervals, significantly improving patient outcomes.

Treatment 82

Treatment 82

Chemical Biology and Drug Design

FEBRUARY 2, 2024

Abstract Existing chemotherapy for neglected tropical diseases (NTDs) can often be toxic and ineffective, highlighting the necessity for new treatments. Their use in combination therapy decreases the concentration of the reference drug used. Terpenes are secondary metabolites with pharmacological potential.

Treatment 100

Treatment Disease Immune Response Therapies 100

PLOS: DNA Science

MARCH 28, 2024

FDA classifies it as a “nonsteroidal treatment” – not a gene therapy, but it affects gene expression. A Scant Protein with Outsize Importance Slowing the muscle decline of DMD presents two huge challenges: the ubiquity of muscle and a giant gene. The gene presents a complex landscape. million DNA bases.

FDA Approval 93

FDA Approval Treatment FDA DNA 93

ASPET

JUNE 4, 2024

The goal of the present study was to determine the antiarthritic potential of the minor cannabinoid 8 -THC using the collagen-induced arthritis (CIA) mouse model. The 8 -THC treatment (30 mg/kg) reduced paw swelling and qualitative signs of arthritis.

Treatment 186

Treatment Disease Production 186

Drug Target Review

OCTOBER 25, 2023

Their findings may result in new treatments for reproductive conditions. He stated that this could inform new treatments for reproductive conditions like recurrent pregnancy loss and preeclampsia. Preeclampsia may present at any gestation but is more commonly encountered in the third trimester.

Treatment 105

Treatment Virus Research Science 105

Chemical Biology and Drug Design

OCTOBER 25, 2023

UAN rats possessed prominent levels of serum creatinine, UA, cys-C, and NGAL, which all reduced after hispidulin treatment in a dose-dependent manner. HE staining determined the improvement of kidney injury after treatment, which was comparable to the efficacy of febuxostat.

Treatment 100

Treatment Drugs Research 100

SCIENMAG: Medicine & Health

JUNE 8, 2023

ECU Centre for Precision Health Clinical Professor Adnan Khattak presented the trial’s latest results at the 2023 American Society of Oncology (ASCO) congress in Chicago this week, the biggest […]

Treatment 90

Treatment Vaccine Trials Research 90

ASPET

OCTOBER 23, 2024

The delayed nature of cerebral ischemia secondary to SAH-related vasculopathy presents a window of opportunity for the evaluation of well-tolerated neuroprotective agents administered soon after ictus. Based on allometric scaling of both toxicological and efficacy data, the therapeutic margin in man should be at least 2.

Clinical Development 100

Clinical Development Treatment Pharmacokinetics Drugs 100

Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). How does the DCI mechanism compare to the design of other drugs for cancer treatment?

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

SCIENMAG: Medicine & Health

MARCH 20, 2024

Milan, Italy: Using a combined scanning technique on patients with early-stage breast cancer improved treatment in almost three out of ten cases in a trial presented at the 14th European Breast Cancer Conference today (Thursday). [1]

Treatment 68

Treatment Doctors Trials 68

Chemical Biology and Drug Design

DECEMBER 15, 2023

Due to the complex pathological processes underlying neurodegeneration, at present, there is no viable therapy available for neurodegenerative disorders. Abstract Neurodegenerative disorders, which affect millions worldwide, are marked by a steady decline of neurons that are selectively susceptible.

Disease 189

Disease Therapies Treatment Research 189

Science Daily: Pharmacology News

JULY 2, 2024

When experimentally testing the effectiveness of these 'treatments,' not only did they aid in recovery, but the research team found the ants' choice of care catered to the type of injury presented to them.

Treatment 130

Treatment Research 130

ASPET

SEPTEMBER 22, 2023

These results suggest that brain damage can be long-lasting or permanent if nerve agent-induced SE in infant victims is treated with midazolam at a delayed timepoint after SE onset, while antiglutamatergic treatment with tezampanel and caramiphen provide significant neuroprotection.

Treatment 100

Treatment FDA Drugs 100

ASPET

JULY 13, 2023

Significance Statement Results presented in this paper, for the first time, implicate the dynamin DNM2 in ocular surface epitheliopathy. We conclude that exposure to tBHP or nitrogen mustard, two different oxidative stress agents, cause corneal epitheliopathy via different pathological pathways.

Small Molecule 100

Small Molecule Treatment 100

Drug Target Review

MAY 23, 2024

What is the main advantage of TriTCE Co-Stim over conventional CD3-engaging bispecific T cell engagers (TCEs) in the treatment of solid tumours? These challenges are related in part to limited intratumoural T cell availability and poor T cell function (T cell anergy) commonly present in solid tumours. The lead CLDN18.2

Treatment 69

Treatment Engineering Therapies Research 69

FDA Law Blog: Drug Discovery

NOVEMBER 10, 2024

Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. The Natural History Studies Grants Program funds natural history studies that collect gather data on how rare diseases progress over time without treatment.

Clinical Development 69

Clinical Development Production Clinical Trials Treatment 69

Conversations in Drug Development Trends

NOVEMBER 21, 2023

Despite significant progress, there are more than 6,500 rare diseases without a single approved treatment. There are so many patients suffering from diseases that have no treatments. We are committed to supporting reimbursement and exploring ways to increase patient access to treatments. “We

Disease 78

Disease Treatment Clinical Trials Clinical Development 78

SCIENMAG: Medicine & Health

MARCH 28, 2024

DETROIT – A groundbreaking study published in the journal iScience presents crucial insights into the ocular effects of Zika virus infection during pregnancy and offers promising avenues for therapeutic intervention.

Virus 67

Virus Treatment Research 67

ASPET

NOVEMBER 17, 2023

Ketamine is a new, potent and rapid-acting antidepressant approved for therapy of treatment-resistant depression, which has a different mechanism of action than currently-available antidepressant therapies. It owes its uniquely potent antidepressant properties to a complex mechanism of action, which currently remains unclear.

Therapies 100

Therapies Treatment Drugs 100

Drug Target Review

JANUARY 15, 2024

Monoclonal antibodies (mAbs) targeting tumour-specific antigens play an essential role in the treatment of many cancers. An important limitation of antibodies against tumour antigens is that these agents direct responses to molecular targets present on the surface of the cell.

Engineering 110

Engineering DNA Virus Immune Response 110

Chemical Biology and Drug Design

JANUARY 29, 2024

sPLA 2 inhibitors have been developed for the treatment of inflammatory and other conditions such as cardiovascular disease, arteriosclerosis and rheumatoid arthritis. The three-dimensional structures presented in this review have been published by various research groups and have been deposited in the Protein Data Bank.

Small Molecule 100

Small Molecule Immune Response Treatment Disease 100

Chemical Biology and Drug Design

APRIL 3, 2024

The present review explores the intricate relationship between autophagy and proteostasis in the pathogenesis of neurodegenerative diseases along with the therapeutic interventions to mitigate the same. Abstract Neurodegenerative disorders are devastating disorders characterized by gradual loss of neurons and cognition or mobility impairment.

Disease 100

Disease Treatment Research 100

Chemical Biology and Drug Design

MAY 11, 2023

Abstract Parkinson's disease is among the most common forms of neurodegenerative illness, with present treatment being primarily symptomatic and frequently coming with substantial adverse effects. The figure depicts the neuroprotective role of crocin in Parkinson's disease.

Disease 100

Disease Research Clinical Trials Treatment 100

Drug Target Review

DECEMBER 23, 2024

While these therapies hold great promise for improving cancer treatment outcomes, their development presents significant challenges, especially in achieving the optimal balance between efficacy and safety. Properly managing these toxicities is crucial to enhancing the safety and therapeutic effectiveness of ADC treatments.

Research 52

Research Treatment Therapies Drug Development 52

Chemical Biology and Drug Design

JANUARY 7, 2024

This study presents a design strategy, synthesis, and evaluation of balanced COX inhibitors derived from paracetamol and firocoxib, highlighting their potential therapeutic value in the context of inflammation. A balanced inhibition of COX-1/−2 represents a promising strategy for the development of novel COX-2 inhibitors.

Treatment 100

Treatment Research 100

ASPET

SEPTEMBER 20, 2024

The present studies evaluated the reinforcing effects of both compounds in monkeys under several conditions. Recently, several modafinil analogues reduced cocaine SA in rats and monkeys, including JJC8-088, characterized as "cocaine like" in rats, and JJC8-091, characterized as "atypical" and not SA by rats. mg/kg/injection), and JJC8-091 (0.1-3.0

FDA Approval 100

FDA Approval Treatment FDA Drugs 100

National Drug & Alcohol Research Centre Blog

FEBRUARY 12, 2024

While lower prevalence drugs, may be well known to present a risk of overdose and death, this is not necessarily recognised for alcohol, which is much more widely used. Are these inexperienced drinkers with a low tolerance or seasoned users with long histories of alcohol problems, perhaps receiving treatment for alcohol dependence?

Disease 110

Disease Treatment Drugs Research 110

Chemical Biology and Drug Design

FEBRUARY 23, 2024

In the present work, we report that isoliquiritigenin, a bioactive component of licorice roots, attenuates neuroinflammation of a mice model with subarachnoid hemorrhage through inhibition of NF-κB-mediated NLRP3 inflammasome activation. ISL also repressed NF-κB p65 expression as well as the transport from the cytoplasm to the nucleus.

Treatment 100

Treatment Therapies Drugs Research 100

FDA Law Blog: Biosimilars

DECEMBER 4, 2023

A prescription not issued in the usual course of professional treatment or in legitimate, authorized research is not a prescription within the meaning of the CSA and the pharmacist knowingly filling it, along with the prescriber issuing it, is subject to penalties. 21 U.S.C. § 829; 21 C.F.R. Holiday CVS, L.L.C. d/b/a CVS/Pharmacy, Nos.

Pharmacy 139

Pharmacy Government Treatment Compliance 139

Chemical Biology and Drug Design

DECEMBER 20, 2024

It has been demonstrated that Lycorine (LYD), a naturally occurring active sesquiterpene present in Chinese medicinal plants, exhibits anti-cancer properties across various cancer cell lines. Additionally, LYD treatment significantly activated the STING pathway in NSCLC and induced the expression of CXCL10, CXCL9 and CCL5 in NSCLC cells.

Immune Response 100

Immune Response Treatment Research 100

Chemical Biology and Drug Design

AUGUST 7, 2023

The present review discusses the many synthetic and natural XO inhibitors that have been developed which are found to have greater potency. There is a great interest in the development of new XO inhibitors for the treatment of hyperuricemia and gout.

Disease 100

Disease Treatment Research 100

Chemical Biology and Drug Design

APRIL 26, 2023

Despite the severity, no causal treatment is currently available. The administration of synthetic polymers that present autoantigens in a multivalent manner have been established as promising therapeutic strategies in other autoimmune diseases and may be applied to IgAN.

Therapies 100

Therapies Disease Treatment Research 100

ASPET

JANUARY 23, 2024

The current pharmacological treatments for SCD-associated priapism are limited and focused on acute interventions rather than prevention. Recent preclinical research reported the beneficial effect of treatment with haptoglobin and NO donors.

Disease 100

Disease Therapies Treatment Research 100

ASPET

OCTOBER 12, 2023

Supramolecular nanostructured based delivery systems are emerging as a meaningful approach in treatment of cancer, offering controlled drug release and improved therapeutic efficacy. Different SNs approaches and recent literature reviews on peptide delivery are also presented to the readers.

Therapies 100

Therapies Small Molecule Treatment Drugs 100

Broad Institute

OCTOBER 3, 2024

Largest-ever genetic study of epilepsy finds possible therapeutic targets By Ari Navetta October 3, 2024 Breadcrumb Home Largest-ever genetic study of epilepsy finds possible therapeutic targets Scientists have uncovered new genetic links to different types of epilepsy, which could lead to more tailored treatments.

DNA 133

DNA Doctors Treatment Disease 133

Chemical Biology and Drug Design

APRIL 24, 2023

Raltegravir, an integrase inhibitor approved for the treatment of HIV infection, led to an increase in DNA damage and apoptosis in multiple myeloma that remains as an incurable malignancy. Furthermore, raltegravir treatment altered the mRNA levels of V(D)J recombination and DNA repair genes. 01 for U66 and p  ˂ .0001

DNA 100

DNA Treatment Research 100

Drug Target Review

DECEMBER 29, 2023

It is the most common cause of the end-stage renal disease (ESRD) and despite intensive treatments such as hyperglycaemic control, blood pressure control and the use of renin-angiotensin system blockades, the prevalence of DKD remains high. 2 Although scientific understanding of DKD has improved, the need for specific biomarkers is crucial.

Disease 126

Disease Science Hospitals Treatment 126